Format

Send to

Choose Destination
Nat Rev Cancer. 2007 Feb;7(2):95-106.

Immunostimulatory monoclonal antibodies for cancer therapy.

Author information

1
Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Universidad de Navarra, Pamplona, Spain. imelero@unav.es

Abstract

Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs) directed to immune-receptor molecules is a new and exciting strategy in cancer therapy. This expanding class of agents functions on crucial receptors, either antagonizing those that suppress immune responses or activating others that amplify immune responses. Complications such as autoimmunity and systemic inflammation are problematic side effects associated with these agents. However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results.

PMID:
17251916
DOI:
10.1038/nrc2051
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center